Amgen's Mixed Q2 Results Highlight Obesity Drug Potential, Analysts Focus Shifts To Upcoming Clinical Readouts
Amgen(AMGN) Benzinga·2024-08-08 02:01Amgen(AMGN) Benzinga·2024-08-08 02:01
R1Amgen(AMGN) Benzinga·2024-08-08 02:01 R1Amgen(AMGN) Benzinga·2024-08-08 02:01